2-ethyl-1-methyl-3-propyl-1H-indole | 1415425-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-ethyl-1-methyl-3-propyl-1H-indole
• 英文别名: 2-Ethyl-1-methyl-3-propylindole
• CAS: 1415425-71-6
• 化学式: C₁₄H₁₉N
• 分子量: 201.312
• InChiKey: VWGGJJOUGVGIAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  3-庚醇 、 1-甲基-1-苯肼 在 2-丁烯腈 、 十二羰基三钌 、 2,2'-双(二苯基磷)联苯 、 zinc(II) chloride 作用下， 以 2-甲基-2-丁醇 为溶剂， 反应 3.0h， 生成 2-butyl-1,3-dimethyl-1H-indole 、 2-ethyl-1-methyl-3-propyl-1H-indole
  参考文献：
  名称：

  From Alcohols to Indoles: A Tandem Ru Catalyzed Hydrogen-Transfer Fischer Indole Synthesis

  摘要：

  In a new version of the Fischer indole synthesis, primary and secondary alcohols have been catalytically oxidized in the presence of phenylhydrazines and protic or Lewis acids to give the corresponding indoles. The overall reaction can be accomplished in one step, and the use of alcohols instead of aldehyes or ketones as starting materials has several advantages in terms of a large selection of reagents, easy handling, and safety of the process.

  DOI：

  10.1021/ol3030956

文献信息

• 4H-IMIDAZO[1,2-A]IMIDAZOLES FOR ELECTRONIC APPLICATIONS
  申请人：UDC Ireland Limited

  公开号：EP3640252A1

  公开（公告）日：2020-04-22

  The present invention relates to compounds of formula (I), a process for their production and their use in electronic devices, especially electroluminescent devices. When used as host material for phosphorescent emitters in electroluminescent devices, the compounds of formula (I) may provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.

  本发明涉及式（I）化合物、其生产工艺及其在电子设备，尤其是电致发光设备中的应用。当用作电致发光器件中磷光发光体的主材料时，式（I）化合物可提高电致发光器件的效率、稳定性、可制造性或光谱特性。
• ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND
  申请人：Samsung Electronics Co., Ltd.

  公开号：EP4016656A1

  公开（公告）日：2022-06-22

  An organometallic compound represented by Formula 1:         Formula 1     M1(Ln1)n1(Ln2)n2 wherein Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 0, 1, or 2, n2 is 1, 2, or 3, wherein CY1, CY2, CY3, R10, R20, R30, X1, X2, Y1 to Y8, and b10 to b30 are as described herein, and wherein * and *' each indicate a binding site to M1.

  由式 1 表示的有机金属化合物： 式 1 M1(Ln1)n1(Ln2)n2 其中 Ln1 是由式 1A 表示的配体，Ln2 是由式 1B 表示的配体，n1 是 0、1 或 2，n2 是 1、2 或 3、 其中 CY1、CY2、CY3、R10、R20、R30、X1、X2、Y1 至 Y8 和 b10 至 b30 如本文所述， * 和 *' 分别表示与 M1 结合的位点。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20170312292A1

  公开（公告）日：2017-11-02

  The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.